These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38738967)

  • 1. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients.
    Hajducek DM; Chelle P; Iorio A; Iserman E; Edginton AN
    Haemophilia; 2024 Jul; 30(4):925-932. PubMed ID: 38738967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
    McEneny-King A; Yeung CH; Edginton AN; Iorio A; Croteau SE
    Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
    Arvanitakis A; Berntorp E; Astermark J
    Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.
    Hajducek DM; Chelle P; Hermans C; Iorio A; McEneny-King A; Yu J; Edginton A
    Haemophilia; 2020 May; 26(3):384-400. PubMed ID: 32281726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate
    Chelle P; Yeung CHT; Croteau SE; Lissick J; Balasa V; Ashburner C; Park YS; Bonanad S; Megías-Vericat JE; Nagao A; Wynn T; Corrales-Medina F; Tran H; Sharathkumar A; Chitlur M; Sarmiento S; Edginton A; Iorio A
    Clin Pharmacokinet; 2020 Feb; 59(2):245-256. PubMed ID: 31435896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
    Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K;
    J Thromb Haemost; 2021 Aug; 19(8):1896-1906. PubMed ID: 34013558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
    Chelle P; Yeung CHT; Bonanad S; Morales Muñoz JC; Ozelo MC; Megías Vericat JE; Iorio A; Spears J; Mir R; Edginton A
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):427-438. PubMed ID: 31115857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
    Nagao A; Yeung CHT; Germini F; Suzuki T
    Thromb Res; 2019 Jan; 173():79-84. PubMed ID: 30496937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time.
    Stonebraker JS; O'Mahony B; Noone D; Iorio A
    Haemophilia; 2021 Sep; 27(5):e596-e608. PubMed ID: 34145693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.